---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-311777"
form_type: "8-K"
ticker: "VOR"
cik: "0001817229"
company_name: "Vor Biopharma Inc."
filed_at: "2022-12-23T23:59:59+00:00"
generated_at: "2026-06-20T23:29:52.590957+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Vor Biopharma enters into $125M at-the-market equity sales agreement with Stifel

## Summary
- Agreement with Stifel for up to $125M of common stock sales in at-the-market offerings.
- Stifel will receive a commission of 3.0% of gross sales proceeds from shares sold.
- Replaces prior ATM agreement with Jefferies LLC, which was terminated on Dec 22, 2022.
- Company has no obligation to sell shares; sales are at its sole discretion.
- Prospectus supplement filed under existing Form S-3 registration statement (333-263541).

## SEC filing metadata
- accession: 0001193125-22-311777
- form_type: 8-K
- ticker: VOR
- cik: 0001817229
- company_name: Vor Biopharma Inc.
- filed_at: 2022-12-23T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1817229/000119312522311777/0001193125-22-311777-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1817229/000119312522311777/d402595d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-311777
- JSON: https://secwatch.observer/filing/0001193125-22-311777.json
- Plain text: https://secwatch.observer/filing/0001193125-22-311777.txt

## Key facts
- Material Agreements
  Vor Biopharma Inc. entered into At-the-Market Equity Offering Sales Agreement with Stifel, Nicolaus & Company, Incorporated valued at up to $125.0 million (effective 2022-12-23).
  - Action: entry
  - Agreement: atm program
  - Counterparty: Stifel, Nicolaus & Company, Incorporated
  - Value: up to $125.0 million
  - Effective: 2022-12-23
  source text: On December 23, 2022, Vor Biopharma Inc. (the “ Company ”) entered into an At-the-Market Equity Offering Sales Agreement (the “ Agreement ”) with Stifel, Nicolaus & Company, Incorporated (“ Stifel ”) under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.0001 per share (the “ Common Stock ”), having an aggregate offering price of up to $125.0 million after the date of the Agreement through Stifel as its sales agent.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1817229/000119312522311777/0001193125-22-311777-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.